• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

    7/6/23 2:30:25 PM ET
    $NYXH
    Medical/Dental Instruments
    Health Care
    Get the next $NYXH alert in real time by email
    SC 13G/A 1 d529193dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Nyxoah SA

    (Name of Issuer)

    Ordinary Shares

    (Title of Class of Securities)

    B6S7WD106

    (CUSIP Number)

    March 30, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. B6S7WD106    13G    Page 2 of 5

     

      1.    

      Names of Reporting Persons

     

      ResMed Inc.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.     

      Sole Voting Power

     

      1,619,756

       6.   

      Shared Voting Power

     

      0

       7.   

      Sole Dispositive Power

     

      1,619,756

       8.   

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,619,756

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      5.65% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Based on an aggregate amount of 28,661,985 ordinary shares (“Ordinary Shares”) of Nyxoah SA (the “Issuer”), of which 25,846,279 Ordinary Shares stated to be outstanding in the Issuer’s Form 20-F furnished to the Securities and Exchange Commission (“SEC”) on March 22, 2023 and an additional 2,815,706 Ordinary Shares reported outstanding by Issuer pursuant to most recent transparency notifications.


    CUSIP No. B6S7WD106    13G    Page 3 of 5

     

    EXPLANATORY NOTE

    This Amendment No. 1 to Schedule 13G is being filed to correct an underreporting of securities beneficially owned and related ownership adjustments by the Reporting Person due to an administrative error.

     

    Item 1.

    (a) Name of issuer

    Nyxoah SA (the “Issuer”).

    (b) Address of issuer’s principal executive offices

    Rue Edouard Belin 12

    1435 Mont-Saint-Guibert, Belgium

     

    Item 2.

    (a) Name of person filing

    ResMed Inc. (the “Reporting Person”).

    (b) Address or principal business office or, if none, residence

    9001 Spectrum Center Blvd.

    San Diego, CA 92123

    (c) Citizenship

    Delaware

    (d) Title of class of securities

    Ordinary Shares

    (e) CUSIP No.

    B6S7WD106

     

    Item 3.

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable

     

    Item 4.

    Ownership

    The responses to Items 5-11 of the cover page of this Schedule 13G are incorporated herein by reference.

     

    (a)

    Amount beneficially owned: 1,619,756 Ordinary Shares

     

    (b)

    Percent of class: 5.65%

     

    (c)

    Number of shares as to which the person has:

     

    (i)

    Sole power to vote or to direct the vote: 1,619,756

     

    (ii)

    Shared power to vote or to direct the vote: 0

     

    (iii)

    Sole power to dispose of or to direct the disposition of: 1,619,756

     

    (iv)

    Shared power to dispose of or to direct the disposition of: 0


    CUSIP No. B6S7WD106    13G    Page 4 of 5

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: July 6, 2023

     

    RESMED INC.
    By:   /s/ Brett Sandercock
    Name: Brett Sandercock
    Its: Chief financial officer
    Get the next $NYXH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NYXH

    DatePrice TargetRatingAnalyst
    7/31/2023Buy
    H.C. Wainwright
    7/19/2023Neutral
    Robert W. Baird
    4/21/2022$30.00Outperform
    Oppenheimer
    4/6/2022$21.00Peer Perform
    Wolfe Research
    12/21/2021$47.00Overweight
    Cantor Fitzgerald
    7/28/2021$43.00Overweight
    Cantor Fitzgerald
    7/28/2021$40.00Overweight
    Piper Sandler
    7/27/2021$43.00Buy
    Stifel
    More analyst ratings

    $NYXH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

      Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's

      5/7/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Conditional Issuance of Shares

      INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), today announced a conditional issuance of up to 5 million ordinary shares under its existing at-the-market equity offering programs (the "ATM"). This brings the aggregate number of ordinary shares that can be sold and issued under the Company's ATM to 5,662,694 (the "ATM Shares"), which includes 662,694 shares that are still available from the conditional issuance of shares under the ATM decided upon on December 22, 2022. Pursuant to the existing sales agreement entered into

      4/16/25 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Provides Update on FDA Approvable Letter for Genio System

      Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), which develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an update on the FDA approval process for the Genio system. On March 26, 2025, the Company announced that the U.S. Food and Drug Administration (FDA) issued an Approvable Letter regarding the Company's Pre-Market Approval (PMA) application for the Genio® system. The Approvable L

      4/8/25 1:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    SEC Filings

    See more
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      4/16/25 6:00:43 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form 6-K filed by Nyxoah SA

      6-K - Nyxoah SA (0001857190) (Filer)

      4/8/25 6:02:10 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nyxoah SA

      EFFECT - Nyxoah SA (0001857190) (Filer)

      4/2/25 12:15:23 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Leadership Updates

    Live Leadership Updates

    See more
    • Nyxoah Appoints John Landry as Chief Financial Officer

      Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. Mr. Landry

      11/4/24 4:45:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Appoints Scott Holstine as Chief Commercial Officer

      Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch. Scott brings over 26 years of experience in the medical device industry with a proven track record in U.S. product launches, building and leading commercial organizations trademarked by

      7/15/24 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Strengthens its Executive Leadership Team

      Nyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer Mont-Saint-Guibert, Belgium – November 28, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (NASDAQ:NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Francis Kim as Chief Regulatory and Quality Officer. Francis will be leading Nyxoah's Global Regulatory and Quality departments. Francis is a highly experienced global regulatory and quality executive in the healthcare industry, having spent more than 25 years in the medical device

      11/28/23 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Nyxoah S.A.

      H.C. Wainwright initiated coverage of Nyxoah S.A. with a rating of Buy

      7/31/23 8:05:01 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Robert W. Baird initiated coverage on Nyxoah S.A.

      Robert W. Baird initiated coverage of Nyxoah S.A. with a rating of Neutral

      7/19/23 7:19:37 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Oppenheimer initiated coverage on Nyxoah S.A. with a new price target

      Oppenheimer initiated coverage of Nyxoah S.A. with a rating of Outperform and set a new price target of $30.00

      4/21/22 7:16:59 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Financials

    Live finance-specific insights

    See more
    • Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025

      Nyxoah to Release First Quarter 2025 Financial Results on May 14, 2025 Mont-Saint-Guibert, Belgium – Wednesday May 7, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the first quarter of 2025 on Wednesday, May 14, 2025. Company management will host a conference call to discuss financial results that day beginning 2:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's

      5/7/25 4:30:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating Results

      REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Financial Year 2024 Financial and Operating ResultsFDA PMA Application Review Nearing ConclusionPositioned for U.S. Commercial Launch in March 2025 Mont-Saint-Guibert, Belgium – March 13, 2024, 7:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the fourth quarter and financial year 2024.   Recent Financial and Operating Highlights Revenue for the fourth quarter of 2024 was €1.3 million, which excludes €0.6 million of deferred rev

      3/13/25 2:00:00 AM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025

      Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025 Mont-Saint-Guibert, Belgium – Monday, March 10, 2025, 10:05pm CET / 5:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will release financial results for the fourth quarter and financial year 2024 on Thursday, March 13, 2025. Company management will host a conference call to discuss financial results that day beginning 1:00pm CET / 8:00am ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxo

      3/10/25 5:05:00 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care

    $NYXH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nyxoah SA

      SC 13D/A - Nyxoah SA (0001857190) (Subject)

      10/10/24 4:00:17 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13D/A filed by Nyxoah SA (Amendment)

      SC 13D/A - Nyxoah SA (0001857190) (Subject)

      5/30/24 5:20:40 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Nyxoah SA (Amendment)

      SC 13G/A - Nyxoah SA (0001857190) (Subject)

      2/14/24 4:17:59 PM ET
      $NYXH
      Medical/Dental Instruments
      Health Care